Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

ACceptance of Therapy In Vardenafil-treated patients with Erectile dysfunction (ACTIVE): a noninterventional study in Germany

International Journal of Impotence Research volume 22, pages 61–67 (2010)Cite this article

Abstract

Cardiovascular and metabolic conditions are risk factors for ED and are common among men with ED. The purpose of this study was to assess the safety and effectiveness of, and notably patient satisfaction with, vardenafil treatment in a general population of men with ED, including those with underlying conditions, over a period of 3–12 months. A prospective, multicenter, noninterventional study was carried out in Germany between July 2005 and January 2007. Men aged ⩾18 years (n=7088) who were prescribed vardenafil for ED, irrespective of previous ED treatment or underlying conditions, were eligible for inclusion. Safety, effectiveness and patient satisfaction data were collected by physician case report forms (CRFs) after 3 months, with optional self-completed patient questionnaires at baseline, 3, 6, 9 and 12 months. The intent-to-treat population included 6474 patients, and 1331 patients returned at least one questionnaire. No serious adverse events were related to vardenafil use. CRF data showed that 93.0% of patients reported improved erections after 3 months, with similar rates of improvement among men with underlying conditions. High levels of patient satisfaction with vardenafil regarding effectiveness of treatment, time to onset and duration of action were sustained throughout the study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. NIH. NIH consensus conference. Impotence. NIH consensus development panel on impotence. JAMA 1993; 270: 83–90.

    Article  Google Scholar 

  2. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M . The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607–617.

    Article  PubMed  Google Scholar 

  3. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.

    CAS  PubMed  Google Scholar 

  4. Eardley I, Lee JC, Guay AT . Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. Int J Clin Pract 2008; 62: 1594–1603.

    Article  CAS  PubMed  Google Scholar 

  5. Guay AT . ED2: erectile dysfunction=endothelial dysfunction. Endocrinol Metab Clin North Am 2007; 36: 453–463.

    Article  PubMed  Google Scholar 

  6. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS . Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004; 64: 1196–1201.

    Article  PubMed  Google Scholar 

  7. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005; 174: 230–239.

    Article  PubMed  Google Scholar 

  8. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806–815.

    Article  PubMed  Google Scholar 

  9. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763–771.

    CAS  PubMed  Google Scholar 

  10. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  PubMed  Google Scholar 

  11. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–1336.

    Article  CAS  PubMed  Google Scholar 

  12. Brock G . Oral agents: first-line therapy for erectile dysfunction. Eur Urol Suppl 2002; 1: 12–18.

    Article  CAS  Google Scholar 

  13. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M . Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3: 883–891.

    Article  CAS  PubMed  Google Scholar 

  14. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T . Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777–783.

    Article  CAS  PubMed  Google Scholar 

  15. Shabsigh R, Duval S, Shah M, Regan TS, Juhasz M, Veltry LG . Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin 2007; 23: 2453–2460.

    Article  CAS  PubMed  Google Scholar 

  16. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M . Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856–864.

    Article  CAS  PubMed  Google Scholar 

  17. Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008; 5: 1455–1467.

    Article  CAS  PubMed  Google Scholar 

  18. Cheng E . Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction—results from 30 010 US patients. J Sex Med 2007; 4: 432–439.

    Article  CAS  PubMed  Google Scholar 

  19. van Ahlen H, Zumbe J, Stauch K, Landen H . The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study—results from 29 358 German patients. J Int Med Res 2005; 33: 337–348.

    Article  CAS  PubMed  Google Scholar 

  20. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    Article  CAS  PubMed  Google Scholar 

  21. Eardley I, Lee JC, Shabsigh R, Dean J, Maggi M, Neuser D et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medication. J Sex Med (in press).

  22. de Tejada IS . Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 2004; 16 (Suppl 1): S40–S42.

    Article  PubMed  Google Scholar 

  23. Valiquette L, Montorsi F, Auerbach S . First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract 2006; 60: 1378–1385.

    Article  CAS  PubMed  Google Scholar 

  24. Montorsi F, Padma-Nathan H, Buvat J, Schwaibold H, Beneke M, Ulbrich E et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004; 1: 168–178.

    Article  CAS  PubMed  Google Scholar 

  25. Hatzichristou DG, Aliotta P, Auerbach S, Barkin J, Lording D, Murdock M et al. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis. Clin Ther 2005; 27: 1452–1461.

    Article  CAS  PubMed  Google Scholar 

  26. Bayer Schering Pharma. Levitra 5 mg, 10 mg, 20 mg film-coated tablets summary of product characteristics 2009.

  27. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I . Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 1037–1049.

    Article  CAS  PubMed  Google Scholar 

  28. Rosen RC, Fisher WA, Beneke M, Homering M, Evers T . The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. BJU Int 2007; 99: 849–859.

    Article  PubMed  Google Scholar 

  29. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007; 100: 130–136.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by Bayer Schering Pharma AG. Editorial assistance was provided by Fishawack Communications during the preparation of this paper, and funded by Bayer Schering Pharma AG.

Author information

Authors and Affiliations

  1. Urologische Klinik, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany

    H Sperling

  2. PUR/R Praxisklinik Urologie Rhein-Ruhr, Mülheim an der Ruhr, Germany

    T Schneider

  3. Bayer Vital GmbH, Leverkusen, Germany

    J U Hanisch

Authors
  1. H Sperling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J U Hanisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Sperling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sperling, H., Schneider, T. & Hanisch, J. ACceptance of Therapy In Vardenafil-treated patients with Erectile dysfunction (ACTIVE): a noninterventional study in Germany. Int J Impot Res 22, 61–67 (2010). https://doi.org/10.1038/ijir.2009.52

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2009.52

Keywords

Search

Advanced search

Quick links